ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1223

Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis

Caitlyn L. Holmes1, Chloe Peyton2, Amy Bier3, Tobias Donlon2, Christie M. Bartels4 and Miriam A. Shelef5,6, 1University of Wisconsin - Madison, Madison, WI, 2University of Minnesota Medical School, Minneapolis, MN, 3Stritch School of Medicine of Loyola University Chicago, Chicago, IL, 4Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, 5Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 6William S. Middleton Memorial Veterans Hospital, Madison, WI

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Antibodies, rheumatoid arthritis (RA) and vaccines

Session Information

Date: Monday, October 22, 2018

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response to vaccination with rheumatoid arthritis patients showing a reduced response to some vaccine antigens, but relatively normal antibody titers in response to others, like the highly efficacious tetanus vaccine. Little is known about the response to pertussis vaccination in rheumatoid arthritis, a concerning omission given the relatively low efficacy of the pertussis vaccine, the rise in pertussis infections in the last 20 years, and the increased susceptibility of rheumatoid arthritis patients to infection. The purpose of this study is to determine if pertussis titers are reduced in vaccinated subjects with rheumatoid arthritis versus controls as well as to determine if clinical factors in rheumatoid arthritis, including the use of immune suppressing medications, correlate with pertussis titers.

Methods: Serum from 98 subjects with seropositive rheumatoid arthritis not using rituximab (a B cell depleting drug) and 77 controls, all vaccinated within 10 years of serum collection with the Tdap (tetanus, diphtheria, and pertussis) vaccine, were selected from our biorepository. Serum was subjected to enzyme-linked immunosorbent assay to detect IgG titers against pertussis and tetanus toxoid. Titers were compared by unpaired t-test and the rates of immunity based on manufacturer cut-offs were compared by a Fisher’s exact test. Univariate and multivariate logistic regression was used to identify clinical factors that correlate with pertussis titers. A p value <0.05 was considered significant.

Results: Subjects with rheumatoid arthritis had significantly lower IgG titers against pertussis, but not tetanus, compared to controls and fewer rheumatoid arthritis subjects were immune to pertussis. At less than 5 years post-vaccination, there was no significant difference in pertussis titers between rheumatoid arthritis patients and controls. However, at 5-10 years post-vaccination, rheumatoid arthritis patients had 50% lower titers than controls and fewer rheumatoid arthritis subjects met immune thresholds. Multivariate regression demonstrated that rheumatoid arthritis, female sex, and longer length of time since vaccination correlated with lower than median pertussis titers. Interestingly, the use of leflunomide or methotrexate at the time of serum collection correlated with higher and lower than median pertussis titers, respectively. No correlation was seen between TNF-inhibiting medications and pertussis titer.

Conclusion: Patients with rheumatoid arthritis have lower IgG titers against pertussis, especially 5-10 years post-vaccination. Reduced titers could be due to the relatively low efficacy of the pertussis vaccine, a dysregulated immune system in rheumatoid arthritis, and/or the use of certain medications. Future studies are needed to determine the mechanism for reduced immunity to pertussis, if more frequent vaccination would improve titers against pertussis, and if susceptibility to pertussis infection is increased in patients with rheumatoid arthritis.


Disclosure: C. L. Holmes, None; C. Peyton, None; A. Bier, None; T. Donlon, None; C. M. Bartels, Pfizer, Inc., 2; M. A. Shelef, None.

To cite this abstract in AMA style:

Holmes CL, Peyton C, Bier A, Donlon T, Bartels CM, Shelef MA. Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/reduced-antibody-titers-against-pertussis-in-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-antibody-titers-against-pertussis-in-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology